EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Dual‐Biologic Therapy in Refractory Bullous Pemphigoid: A Focused Review of Rituximab–Omalizumab and Omalizumab–Dupilumab

Mohammed Shanshal

Dermatologic Therapy · 2026-01 · 2026 (1)

DOI: 10.1155/dth/1532359 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Dermatologic Therapy, online erschienen am 28.06.2026. Verfasst von Mohammed Shanshal. Die Arbeit nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Bullous pemphigoid (BP) is the commonest autoimmune subepidermal blistering disease. Refractory cases and patients with comorbidities limiting conventional immunosuppression remain difficult to treat. Dual‐biologic therapy has emerged as a rescue strategy.

Methods

We reviewed PubMed and Embase from inception to 1 April 2026 for reports of overlapping dual‐biologic therapy in BP. Six peer‐reviewed studies describing rituximab plus omalizumab (ROCT) or omalizumab plus dupilumab (DOCT) were included for descriptive synthesis.

Results

Six studies comprising 37 patients were identified (27 ROCT and 10 DOCT). In the largest comparative ROCT cohort, all 17 combination‐treated patients achieved disease control versus 23 of 25 (92%) receiving rituximab alone, with faster disease control (15 vs. 67.5 days) and lower 60‐day methylprednisolone exposure (698.4 vs. 1087.4 mg). High‐dose omalizumab plus rituximab achieved complete remission in 7 of 7 patients. DOCT showed favorable responses but remained small, uncontrolled, and partly confounded by concomitant mycophenolate mofetil in 3 of 10 patients. No treatment‐attributable combination‐specific safety signal was identified.

Conclusions

Dual‐biologic therapy in BP was concentrated in ROCT and DOCT pairings, used mainly in refractory disease or when conventional immunosuppression was constrained by comorbidity. ROCT carries the stronger signal, whereas DOCT remains promising but exploratory. Prospective multicenter studies are needed.

Zitieren

APA

Shanshal, M. (2026). Dual‐Biologic Therapy in Refractory Bullous Pemphigoid: A Focused Review of Rituximab–Omalizumab and Omalizumab–Dupilumab. Dermatologic Therapy, 2026(1). https://doi.org/10.1155/dth/1532359

Vancouver

Shanshal M. Dual‐Biologic Therapy in Refractory Bullous Pemphigoid: A Focused Review of Rituximab–Omalizumab and Omalizumab–Dupilumab. Dermatologic Therapy. 2026;2026(1). doi:10.1155/dth/1532359

BibTeX
@article{Shanshal2026,
  author = {Shanshal, Mohammed},
  title = {Dual‐Biologic Therapy in Refractory Bullous Pemphigoid: A Focused Review of Rituximab–Omalizumab and Omalizumab–Dupilumab},
  journal = {Dermatologic Therapy},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/dth/1532359}
}
Kostenlos starten →